← Back to Search

OcuMet Beacon for Age-Related Macular Degeneration (FPF in AMD Trial)

N/A

Recruiting

Led By Mihai Mititelu, MD, MPH

Research Sponsored by University of Wisconsin, Madison

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Established diagnosis of GA due to AMD

Be older than 18 years old

Must not have

Presence of concurrent retinal disease which may confound assessment

Presence of neovascular AMD on OCT as confirmed by an ophthalmologist

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 45 minutes

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to see if stressed cells in the retina match up with areas of disease seen in standard imaging and if these images can help identify potential problem areas before symptoms appear. The main focus is on

Who is the study for?

This trial is for individuals with Age-Related Macular Degeneration (AMD), a condition affecting the retina. It's designed to see if stressed cells in the retina show up in specific imaging before symptoms appear or the disease progresses.

What is being tested?

The study tests how well FPF imaging using OcuMet Beacon can detect areas of retinal cell stress and potential early signs of AMD progression, compared to standard imaging techniques.

What are the potential side effects?

Since this trial involves non-invasive retinal imaging, there are minimal side effects expected. Participants may experience discomfort from bright lights during the imaging process.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with geographic atrophy due to age-related macular degeneration.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have an eye condition that could affect vision tests.

Select...

My eye doctor confirmed I have wet AMD.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 45 minutes

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 45 minutes

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 45 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Limits of agreement between the fundus autofluorescence (FAF) area of GA images taken with the Heidelberg Spectralis to the flavoprotein fluorescence (FPF) area of GA with images taken with the OcuMet Beacon